Home World News Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses... World News Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis By Ogkologos - June 18, 2026 262 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SENTRY study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Colorectal Cancer Screening: The Silver Lining September 1, 2020 10 Ways You Can Nurture A More Sustainable Garden June 18, 2021 The Investigational PD1 Antibody, Tislelizumab, Shows Promise in Patients With Unresectable... July 1, 2021 Associations Between Genomic Features and Response to Neoadjuvant Treatment in a... August 30, 2022 Load more HOT NEWS Exosomes May Help Tumors Evade Immune System Treatment with a Hypomethylating Agent Can Activate or Up-regulate Oncogenes Delayed irAEs Occur in a Small Subset of Patients with Melanoma,... Opinion: ‘The UK must be more ambitious than just clearing the...
